Long-term Follow-Up of a Phase 1 Study of Arlocabtagene Autoleucel (arlo-cel; BMS-986393) in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM)
Susan Bal(University of Alabama at Birmingham Hospital), Jesús G. Berdeja(Tennessee Oncology), Myo Htut(City Of Hope National Medical Center), Allison Kaeding(Bristol-Myers Squibb (United States)), Ziyan Guo(Bristol-Myers Squibb (Sweden)), Larry D. Anderson(Dana-Farber Cancer Institute), Tara Gregory(Colorado Blood Cancer Institute), Luciano J. Costa(University of Alabama at Birmingham), Omar Nadeem(Harvard University), Mehmet H. Kocoglu(University of Maryland, Baltimore), Naomey Sarkis(Bristol-Myers Squibb (United States)), Michael R. Burgess(Bristol-Myers Squibb (United States)), Wei-Ming Kao(Bristol-Myers Squibb (United States)), Hongxiang Hu(Bristol-Myers Squibb (United States)), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Adriana Rossi, Kristina M. Jordahl(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505